Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
J Med Chem. 2021 Feb 11;64(3):1584-1592. doi: 10.1021/acs.jmedchem.0c01768. Epub 2021 Feb 1.
Increased activity of the lysine methyltransferase NSD2 driven by translocation and activating mutations is associated with multiple myeloma and acute lymphoblastic leukemia, but no NSD2-targeting chemical probe has been reported to date. Here, we present the first antagonists that block the protein-protein interaction between the N-terminal PWWP domain of NSD2 and H3K36me2. Using virtual screening and experimental validation, we identified the small-molecule antagonist , which binds to the NSD2-PWWP1 domain with a of 3.4 μM and abrogates histone H3K36me2 binding to the PWWP1 domain in cells. This study establishes an alternative approach to targeting NSD2 and provides a small-molecule antagonist that can be further optimized into a chemical probe to better understand the cellular function of this protein.
由易位和激活突变驱动的赖氨酸甲基转移酶 NSD2 的活性增加与多发性骨髓瘤和急性淋巴细胞白血病有关,但迄今为止尚未报道针对 NSD2 的靶向化学探针。在这里,我们首次提出了阻断 NSD2 的 N 端 PWWP 结构域与 H3K36me2 之间的蛋白-蛋白相互作用的拮抗剂。通过虚拟筛选和实验验证,我们鉴定出小分子拮抗剂 ,它与 NSD2-PWWP1 结构域的结合亲和力为 3.4 μM,并在细胞中阻断组蛋白 H3K36me2 与 PWWP1 结构域的结合。这项研究为靶向 NSD2 建立了一种替代方法,并提供了一种小分子拮抗剂,可以进一步优化为化学探针,以更好地了解该蛋白质的细胞功能。